- Market Capitalization, $K 2,333,082
- Shares Outstanding, K 393,437
- Annual Sales, $ 614,060 K
- Annual Income, $ -18,000 K
- 60-Month Beta 2.35
- Price/Sales 3.84
- Price/Cash Flow N/A
- Price/Book 3.75
|Period||Period Low||Period High||Performance|
| || |
-1.42 (-21.85%)since 03/12/21
| || |
-0.88 (-14.77%)since 01/13/21
| || |
-1.31 (-20.50%)since 04/13/20
Marks first and only EC-approved treatment to reduce cardiovascular risk in high-risk, statin-treated adult patients who have elevated triglycerides (greater-than or equal to150 mg/dL) and other risk characteristics...
Recent recommendations or guidances, from Canada and Egypt, expand the global recognition of this important therapy and its demonstrated favorable outcomes study results
HLS Therapeutics Announces that Icosapent Ethyl (Vascepa®) is Included in the 2021 Canadian Cardiovascular Society (CCS) Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular...
HLS Therapeutics Announces that VASCEPA® (Icosapent Ethyl) is Found in Prespecified and Post Hoc Analyses to Significantly Reduce Stroke in At-Risk Patients in Analyses of Landmark REDUCE-IT® Study Presented...
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...
Amarin's (AMRN) revenue growth in the fourth quarter is attributable to continued demand for its cardiovascular drug, Vascepa.
Investors in Amarin Corp plc saw new options begin trading this week, for the May 21st expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value,...
Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, is scheduled to present general company updates at the following investor conferences...
Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the company's fourth quarter and full year 2020 financial results...
HLS Therapeutics Provides Update on Private and Public Payer Reimbursement for Vascepa®